Infiltration - EXPAREL — Competitive Intelligence Brief

Infiltration - EXPAREL (Infiltration - EXPAREL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting local anesthetic. Area: Anesthesia / Pain Management.

marketed Long-acting local anesthetic Voltage-gated sodium channels Anesthesia / Pain Management Small molecule

Target snapshot

Infiltration - EXPAREL (Infiltration - EXPAREL) — Pacira Pharmaceuticals, Inc. EXPAREL is a long-acting local anesthetic that blocks sodium channels in nerve fibers to provide prolonged infiltration anesthesia and post-operative pain relief.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Infiltration - EXPAREL TARGET	Infiltration - EXPAREL	Pacira Pharmaceuticals, Inc	marketed	Long-acting local anesthetic	Voltage-gated sodium channels
Bupivacaine-adrenaline	Bupivacaine-adrenaline	University of Aarhus	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)
Bupivacain/levobupivacaine	Bupivacain/levobupivacaine	University Hospital, Basel, Switzerland	marketed	Local anesthetic	Voltage-gated sodium channels
Permethrin Cream, 5%	Permethrin Cream, 5%	Mayne Pharma International Pty Ltd	marketed	Synthetic pyrethroid insecticide	Voltage-gated sodium channels (arthropod nervous system)
All registered antiepileptic drugs	All registered antiepileptic drugs	UMC Utrecht	marketed	Antiepileptic drugs (heterogeneous class)	Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent
Bupivacaine Spinal 0,5% Heavy - bolus	Bupivacaine Spinal 0,5% Heavy - bolus	Centre of Postgraduate Medical Education	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
prilocaine 1%	prilocaine 1%	Helios Research Center	marketed	Local anesthetic (amide)	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting local anesthetic class)

1. Pacira Pharmaceuticals, Inc · 2 drugs in this class